Clinical trial
Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer
NCT00297596 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00297596 |
|---|---|
| Title | Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer |
| Official title | A Phase II Trial of Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Trastuzumab, Oxaliplatin |
| Enrollment | 25 |
| Start date | Feb 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2010 |
| First posted | Feb 28, 2006 |
| Last update posted | Oct 28, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: